Skip to main content
Premium Trial:

Request an Annual Quote

Atonarp Raises $50M in Series D Round

NEW YORK — Japanese molecular diagnostics firm Atonarp said on Tuesday that it has raised $50 million in a Series D financing round, bringing its total funding to date to $111 million.

The financing round was led by WRVI Capital, with participation from Furukawa Electric, Japan Post Investment, Boscolo Intervest, ATI Korea, and Banner Industries. In conjunction with the financing, Michael Marks, WRVI's founding partner, has joined Atonarp's board of directors.

Atonarp, based in Tokyo, said it will use the money to support the development and commercialization of its molecular diagnostic products and to expand its operations to meet growing customer demand.

Among Atonarp's current offerings is its Aton-360 nonlinear optical spectroscopy instrument for point-of-care blood analysis, continuous patient monitoring, and cell line quantification. The company also markets molecular sensors for pharmaceutical manufacturing and tools for semiconductor manufacturing, and it is developing a non-contact optical diagnostic platform for quantifying analytes in biofluids that is scheduled for release in 2022.

In 2019, Atonarp closed a $33 million Series C round to support its existing mass spectrometry business and to develop its nonlinear optical spectroscopy technology for biosensing and imaging applications.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.